Your browser doesn't support javascript.
loading
Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.
Piñeiro, C; Policarpo, S; Caldas, C; Santos, L; Augusto, I; DiMondi, V P; Serrão, R.
Afiliación
  • Piñeiro C; Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Policarpo S; Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Caldas C; Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Santos L; Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Augusto I; ViiV Healthcare, Algés, Portugal.
  • DiMondi VP; ViiV Healthcare, Durham, North Carolina, USA.
  • Serrão R; Centro Hospitalar Universitário de São João, Porto, Portugal.
HIV Med ; 2024 Sep 06.
Article en En | MEDLINE | ID: mdl-39238426
ABSTRACT

OBJECTIVES:

People living with HIV face several challenges as they age, including the potential for polypharmacy and increased susceptibility to drug-related adverse effects. Thus, effective and well-tolerated regimens with minimal or no drug interactions would be useful in this population. We present real-world effectiveness and safety data for individuals aged >50 years who achieved virological suppression (HIV-1 RNA <50 copies/mL) and switched to dolutegravir/lamivudine (DTG/3TC).

METHODS:

This retrospective, observational, single-centre study conducted in Portugal included individuals aged >50 years who switched to DTG/3TC while virologically suppressed and had ≥12 months of follow-up. Proportions of individuals maintaining virological suppression were described at 12 months; CD4+ cell counts were described at baseline and 12 months. Descriptive subgroup analyses were performed based on age, sex assigned at birth, and availability of historical genotypic resistance results.

RESULTS:

Overall, 538 individuals aged >50 years were included (74% male; mean age, 62 years; mean time on previous therapy, 160 months). High proportions (intention-to-treat population, 97%; on-treatment population, 98%) of individuals who switched to DTG/3TC maintained virological suppression through 12 months of follow-up. CD4+ cell counts remained stable (mean baseline 727 cells/mm3 [range 94-2371]; mean month 12 742 cells/mm3 [range 99-2659]). No individuals experienced virological failure. Nine (2%) individuals discontinued DTG/3TC for non-treatment-related reasons. Proportions with virological suppression at month 12 were similar between on-treatment subgroups by age, sex assigned at birth, and historical genotypic resistance results availability.

CONCLUSIONS:

DTG/3TC demonstrated robust effectiveness and a good safety profile in individuals aged >50 years with virological suppression in Portugal.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: HIV Med Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: HIV Med Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Reino Unido